Cytokine targets in the treatment of myelodysplastic syndromes.

Amit K. Verma, Alan F. List

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) are characterized by refractory cytopenias due to ineffective hematopoiesis in the marrow. Cytokines play an important role in the regulation of hematopoiesis; dysregulation of their levels can lead to hematopoietic failure. Considerable evidence implicates tumor necrosis factor alpha, transforming growth factor beta, interferons, interleukin 1beta, vascular endothelial growth factor (VEGF), and other inhibitory cytokines in the pathogenesis of MDS. These cytokines are produced by the interactions between the MDS clone and the bone marrow microenvironment. Therapeutic strategies therefore may augment the action of stimulatory growth factors or disrupt the effects of myelosuppressive cytokines. Erythropoietin alone and in combination with low-dose granulocyte colony-stimulating factor can lead to erythroid responses in selected patients. Agents targeting inhibitory cytokines include thalidomide, lenalidomide, etanercept, infliximab, VEGF receptor inhibitor PTK-787, antithymocyte globulin, and SCIO-469, a p38 mitogen-activated protein kinase inhibitor. Given the biologic heterogeneity of MDS, no single treatment is effective for all patients with the disease. With more detailed knowledge of cytokine signaling cascades, coupled with technological improvements in genomics and proteomics, the future treatment of this challenging disease may lie in combination therapies customized for relevant biologic effectors.

Original languageEnglish (US)
Pages (from-to)429-435
Number of pages7
JournalCurrent hematology reports.
Volume4
Issue number6
StatePublished - Nov 2005

Fingerprint

Myelodysplastic Syndromes
Cytokines
Hematopoiesis
Therapeutics
Bone Marrow
Vascular Endothelial Growth Factor Receptor
Thalidomide
Antilymphocyte Serum
Interferon-beta
p38 Mitogen-Activated Protein Kinases
Granulocyte Colony-Stimulating Factor
Protein Kinase Inhibitors
Erythropoietin
Genomics
Interleukin-1beta
Transforming Growth Factor beta
Proteomics
Vascular Endothelial Growth Factor A
Intercellular Signaling Peptides and Proteins
Clone Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Cytokine targets in the treatment of myelodysplastic syndromes. / Verma, Amit K.; List, Alan F.

In: Current hematology reports., Vol. 4, No. 6, 11.2005, p. 429-435.

Research output: Contribution to journalArticle

@article{ca93dc4cae2347caabd531263ac9ca37,
title = "Cytokine targets in the treatment of myelodysplastic syndromes.",
abstract = "Myelodysplastic syndromes (MDS) are characterized by refractory cytopenias due to ineffective hematopoiesis in the marrow. Cytokines play an important role in the regulation of hematopoiesis; dysregulation of their levels can lead to hematopoietic failure. Considerable evidence implicates tumor necrosis factor alpha, transforming growth factor beta, interferons, interleukin 1beta, vascular endothelial growth factor (VEGF), and other inhibitory cytokines in the pathogenesis of MDS. These cytokines are produced by the interactions between the MDS clone and the bone marrow microenvironment. Therapeutic strategies therefore may augment the action of stimulatory growth factors or disrupt the effects of myelosuppressive cytokines. Erythropoietin alone and in combination with low-dose granulocyte colony-stimulating factor can lead to erythroid responses in selected patients. Agents targeting inhibitory cytokines include thalidomide, lenalidomide, etanercept, infliximab, VEGF receptor inhibitor PTK-787, antithymocyte globulin, and SCIO-469, a p38 mitogen-activated protein kinase inhibitor. Given the biologic heterogeneity of MDS, no single treatment is effective for all patients with the disease. With more detailed knowledge of cytokine signaling cascades, coupled with technological improvements in genomics and proteomics, the future treatment of this challenging disease may lie in combination therapies customized for relevant biologic effectors.",
author = "Verma, {Amit K.} and List, {Alan F.}",
year = "2005",
month = "11",
language = "English (US)",
volume = "4",
pages = "429--435",
journal = "Current hematology reports.",
issn = "1541-9714",
number = "6",

}

TY - JOUR

T1 - Cytokine targets in the treatment of myelodysplastic syndromes.

AU - Verma, Amit K.

AU - List, Alan F.

PY - 2005/11

Y1 - 2005/11

N2 - Myelodysplastic syndromes (MDS) are characterized by refractory cytopenias due to ineffective hematopoiesis in the marrow. Cytokines play an important role in the regulation of hematopoiesis; dysregulation of their levels can lead to hematopoietic failure. Considerable evidence implicates tumor necrosis factor alpha, transforming growth factor beta, interferons, interleukin 1beta, vascular endothelial growth factor (VEGF), and other inhibitory cytokines in the pathogenesis of MDS. These cytokines are produced by the interactions between the MDS clone and the bone marrow microenvironment. Therapeutic strategies therefore may augment the action of stimulatory growth factors or disrupt the effects of myelosuppressive cytokines. Erythropoietin alone and in combination with low-dose granulocyte colony-stimulating factor can lead to erythroid responses in selected patients. Agents targeting inhibitory cytokines include thalidomide, lenalidomide, etanercept, infliximab, VEGF receptor inhibitor PTK-787, antithymocyte globulin, and SCIO-469, a p38 mitogen-activated protein kinase inhibitor. Given the biologic heterogeneity of MDS, no single treatment is effective for all patients with the disease. With more detailed knowledge of cytokine signaling cascades, coupled with technological improvements in genomics and proteomics, the future treatment of this challenging disease may lie in combination therapies customized for relevant biologic effectors.

AB - Myelodysplastic syndromes (MDS) are characterized by refractory cytopenias due to ineffective hematopoiesis in the marrow. Cytokines play an important role in the regulation of hematopoiesis; dysregulation of their levels can lead to hematopoietic failure. Considerable evidence implicates tumor necrosis factor alpha, transforming growth factor beta, interferons, interleukin 1beta, vascular endothelial growth factor (VEGF), and other inhibitory cytokines in the pathogenesis of MDS. These cytokines are produced by the interactions between the MDS clone and the bone marrow microenvironment. Therapeutic strategies therefore may augment the action of stimulatory growth factors or disrupt the effects of myelosuppressive cytokines. Erythropoietin alone and in combination with low-dose granulocyte colony-stimulating factor can lead to erythroid responses in selected patients. Agents targeting inhibitory cytokines include thalidomide, lenalidomide, etanercept, infliximab, VEGF receptor inhibitor PTK-787, antithymocyte globulin, and SCIO-469, a p38 mitogen-activated protein kinase inhibitor. Given the biologic heterogeneity of MDS, no single treatment is effective for all patients with the disease. With more detailed knowledge of cytokine signaling cascades, coupled with technological improvements in genomics and proteomics, the future treatment of this challenging disease may lie in combination therapies customized for relevant biologic effectors.

UR - http://www.scopus.com/inward/record.url?scp=33644874859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644874859&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 429

EP - 435

JO - Current hematology reports.

JF - Current hematology reports.

SN - 1541-9714

IS - 6

ER -